Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-10-01

FDA Approved: LIALDA — Supplemental Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for LIALDA (mesalamine) from Takeda Pharmaceuticals America, Inc., resulting in updated labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LIALDA (mesalamine)

Snippet

SUPPL AP for LIALDA (MESALAMINE)